Table 1.

Baseline demographics and characteristics (full analysis set)

CharacteristicPlacebo (n=85)Selonsertib 2 mg (n=81)Selonsertib 6 mg (n=84)Selonsertib 18 mg (n=83)Total (N=333)
Mean age (SD), yr62 (7.9)63 (8.1)62 (8.1)63 (9.0)63 (8.3)
Men, n (%)53 (62.4)53 (65.4)64 (76.2)56 (67.5)226 (67.9)
Race, n (%)
 Asian3 (3.5)3 (3.7)4 (4.8)2 (2.4)12 (3.6)
 Black19 (22.4)20 (24.7)23 (27.4)11 (13.3)73 (21.9)
 White61 (71.8)53 (65.4)57 (67.9)68 (81.9)239 (71.8)
 Other2 (2.4)5 (6.1)02 (2.4)9 (2.7)
Hispanic or Latino ethnicity, n (%)30 (35.3)25 (30.9)31 (36.9)33 (39.8)119 (35.7)
Mean body mass index (SD), kg/m234.7 (6.78)34.6 (8.19)a35.6 (8.54)b35.4 (8.06)35.1 (7.89)c
Prior medications of interest, n (%)
 ACEi31 (36.5)33 (40.7)31 (36.9)34 (41.0)129 (38.7)
 ARB44 (51.8)36 (44.4)42 (50.0)39 (47.0)161 (48.3)
Medical history
 Mean serum creatinine (SD), mg/dl2.3 (0.73)2.3 (0.72)2.3 (0.74)2.2 (0.68)2.3 (0.71)
 Mean eGFR (SD), ml/min per 1.73 m231.4 (11.87)31.6 (10.92)31.9 (11.58)31.1 (10.44)31.5 (11.18)
 Diabetes, n (%)68 (80.0)64 (79.0)74 (88.1)67 (80.7)273 (82.0)
  Diabetes: neuropathy43 (50.6)35 (43.2)47 (56.0)42 (50.6)167 (50.2)
  Diabetes: retinopathy27 (31.8)30 (37.0)30 (35.7)24 (28.9)111 (33.3)
  Diabetes: gastroparesis02 (2.5)2 (2.4)04 (1.2)
 Congestive heart failure, n (%)d12 (14.1)12 (14.8)8 (9.5)14 (16.9)46 (13.8)
 Coronary artery bypass graft, n (%)e6 (7.1)8 (9.9)6 (7.1)13 (15.7)33 (9.9)
 Coronary artery disease, n (%)24 (28.2)27 (33.3)20 (23.8)34 (41.0)105 (31.5)
 Dyslipidemia, n (%)68 (80.0)60 (74.1)64 (76.2)66 (79.5)258 (77.5)
  • a n=79.

  • b n=83.

  • c N=330.

  • d All classes were used for each subject if applicable.

  • e The most recent event was collected for each subject.